Mesoblast Limited (MSB.AX)
AUD 3.05
(54.04%)
AUD 3.05
(54.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 63.87 Million USD | -16.82% |
| 2023 | 76.79 Million USD | -15.42% |
| 2022 | 90.78 Million USD | -21.1% |
| 2021 | 115.05 Million USD | 6.97% |
| 2020 | 107.56 Million USD | 9.89% |
| 2019 | 97.88 Million USD | 6.36% |
| 2018 | 92.03 Million USD | -0.5% |
| 2017 | 92.49 Million USD | -6.03% |
| 2016 | 98.43 Million USD | -28.22% |
| 2015 | 137.13 Million USD | 39.43% |
| 2014 | 98.35 Million USD | 10.68% |
| 2013 | 88.86 Million USD | 36.74% |
| 2012 | 64.98 Million USD | 139.28% |
| 2011 | 27.15 Million USD | 143.97% |
| 2010 | 11.13 Million USD | 7.87% |
| 2009 | 10.31 Million USD | 16.61% |
| 2008 | 8.84 Million USD | 1.8% |
| 2007 | 8.69 Million USD | -4.54% |
| 2006 | 9.1 Million USD | 511.37% |
| 2005 | 1.48 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.21 Million USD | 0.0% |
| 2024 Q1 | 3.21 Million USD | -84.58% |
| 2024 FY | 63.87 Million USD | -16.82% |
| 2023 Q3 | 16.4 Million USD | -25.32% |
| 2023 Q4 | 20.87 Million USD | 27.29% |
| 2023 Q1 | 17.5 Million USD | -20.53% |
| 2023 Q2 | 21.96 Million USD | 25.45% |
| 2023 FY | 76.79 Million USD | -15.42% |
| 2022 Q4 | 22.03 Million USD | 3.18% |
| 2022 Q3 | 21.35 Million USD | -13.21% |
| 2022 Q2 | 24.6 Million USD | 7.33% |
| 2022 FY | 90.78 Million USD | -21.1% |
| 2022 Q1 | 22.92 Million USD | 7.66% |
| 2021 Q4 | 21.29 Million USD | -23.48% |
| 2021 Q2 | 28.55 Million USD | -26.53% |
| 2021 Q1 | 38.86 Million USD | 18.89% |
| 2021 Q3 | 27.82 Million USD | -2.57% |
| 2021 FY | 115.05 Million USD | 6.97% |
| 2020 Q3 | 27.72 Million USD | 6.94% |
| 2020 Q4 | 32.69 Million USD | 17.93% |
| 2020 FY | 107.56 Million USD | 9.89% |
| 2020 Q2 | 25.92 Million USD | 26.14% |
| 2020 Q1 | 20.55 Million USD | 5.19% |
| 2019 Q2 | 26.06 Million USD | -8.28% |
| 2019 FY | 97.88 Million USD | 6.36% |
| 2019 Q3 | 22.93 Million USD | -12.03% |
| 2019 Q4 | 19.53 Million USD | -14.8% |
| 2019 Q1 | 28.42 Million USD | 14.55% |
| 2018 Q3 | 24.67 Million USD | 10.42% |
| 2018 FY | 92.03 Million USD | -0.5% |
| 2018 Q4 | 24.81 Million USD | 0.54% |
| 2018 Q2 | 22.34 Million USD | 8.15% |
| 2018 Q1 | 20.66 Million USD | -13.6% |
| 2017 FY | 92.49 Million USD | -6.03% |
| 2017 Q1 | 22.27 Million USD | -18.56% |
| 2017 Q2 | 23.39 Million USD | 5.03% |
| 2017 Q3 | 22.88 Million USD | -2.18% |
| 2017 Q4 | 23.91 Million USD | 4.51% |
| 2016 FY | 98.43 Million USD | -28.22% |
| 2016 Q1 | 21.72 Million USD | -63.19% |
| 2016 Q2 | 24.84 Million USD | 14.38% |
| 2016 Q4 | 27.35 Million USD | 11.56% |
| 2016 Q3 | 24.51 Million USD | -1.32% |
| 2015 Q3 | 24.46 Million USD | -18.75% |
| 2015 FY | 137.13 Million USD | 39.43% |
| 2015 Q4 | 59 Million USD | 141.18% |
| 2015 Q2 | 30.11 Million USD | 81.25% |
| 2015 Q1 | 16.61 Million USD | -13.46% |
| 2014 Q3 | 19.49 Million USD | 21.32% |
| 2014 Q4 | 19.19 Million USD | -1.52% |
| 2014 FY | 98.35 Million USD | 10.68% |
| 2014 Q1 | 17.98 Million USD | 2.95% |
| 2014 Q2 | 16.06 Million USD | -10.69% |
| 2013 Q2 | 17.32 Million USD | 0.06% |
| 2013 Q4 | 17.47 Million USD | -12.05% |
| 2013 Q3 | 19.86 Million USD | 14.65% |
| 2013 FY | 88.86 Million USD | 36.74% |
| 2013 Q1 | 17.31 Million USD | 0.0% |
| 2012 FY | 64.98 Million USD | 139.28% |
| 2011 FY | 27.15 Million USD | 143.97% |
| 2010 FY | 11.13 Million USD | 7.87% |
| 2009 FY | 10.31 Million USD | 16.61% |
| 2008 FY | 8.84 Million USD | 1.8% |
| 2007 FY | 8.69 Million USD | -4.54% |
| 2006 FY | 9.1 Million USD | 511.37% |
| 2005 FY | 1.48 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 39.57 Million AUD | -61.402% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -8893.589% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -973.781% |
| Biome Australia Limited | 7.91 Million AUD | -707.385% |
| Patrys Limited | 4.93 Million AUD | -1194.749% |
| Orthocell Limited | 15.36 Million AUD | -315.588% |
| Imugene Limited | 135.09 Million AUD | 52.718% |
| Noxopharm Limited | 7 Million AUD | -812.461% |
| PYC Therapeutics Limited | 60.91 Million AUD | -4.855% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | -223.129% |
| Prescient Therapeutics Limited | 10.89 Million AUD | -486.065% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -7059.615% |
| Cynata Therapeutics Limited | 11.12 Million AUD | -474.222% |
| CSL Limited | 7.56 Billion AUD | 99.155% |
| Arovella Therapeutics Limited | 10.78 Million AUD | -492.233% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -2213.425% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | -104.09% |
| Starpharma Holdings Limited | 22.81 Million AUD | -179.953% |
| Nanollose Limited | 12.5 Thousand AUD | -510851.124% |
| Memphasys Limited | 3.67 Million AUD | -1636.47% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -1809.033% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -3150.22% |
| Amplia Therapeutics Limited | 8.43 Million AUD | -657.185% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -10513.472% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -1448.327% |
| Race Oncology Limited | 14.77 Million AUD | -332.444% |
| Nyrada Inc. | 4.55 Million AUD | -1302.231% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 76.278% |
| Dimerix Limited | 25.64 Million AUD | -149.087% |
| PharmAust Limited | 6.65 Million AUD | -859.503% |
| Immutep Limited | 42.87 Million AUD | -48.977% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | -13.438% |
| Alterity Therapeutics Limited | 23.4 Million AUD | -172.888% |
| BTC Health Limited | -1.03 Million AUD | 6248.074% |
| Acrux Limited | 8.55 Million AUD | -647.064% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | -95.351% |
| Biotron Limited | 5.11 Million AUD | -1149.815% |
| Tissue Repair Ltd | 6.66 Million AUD | -858.089% |
| AdAlta Limited | 6.76 Million AUD | -843.555% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -21246.264% |
| Hexima Limited | 1 Million AUD | -6231.995% |
| AnteoTech Limited | 12.18 Million AUD | -424.116% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 1.888% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | -194.561% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -1305.247% |
| Actinogen Medical Limited | 22.77 Million AUD | -180.512% |
| Immuron Limited | 9.13 Million AUD | -599.0% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -672.438% |